Furathiocarb
Based on 1 Customer Validation
Furathiocarb is a carbamate pro-insecticide and a contact allergen. Furathiocarb is commonly used in studies related to contact allergy. Furathiocarb induces significant proliferation of MHC II-positive B cells in auricular lymph node cells and induces the production of Th1 cytokines (such as IL-2, TNF-γ and IFN-γ). However, Furathiocarb does not induce respiratory allergy in mice. After absorption through the abdominal skin of isolated rats, Furathiocarb is completely metabolized into carbofuran, and its permeation amount increases with time and dosage. The skin permeation rates of both emulsifiable concentrate (EC) and wettable powder (WP) formulations of Furathiocarb are higher than that of Furathiocarb itself, with no significant difference between the two formulations.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.21%
- CAS. Nr.: 65907-30-4
- Formel: C18H26N2O5S
- Molecular Weight:382.48
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
In Vivo
After long-term skin sensitization and intratracheal challenge in female BALB/c mice with Furathiocarb (1% for sensitization, 0.01-0.1% for challenge; sensitization is administered topically, challenge is administered intratracheally; sensitization is performed on days 1-3, 8-10, and 15-17, with a single challenge dose given on day 31), no significant Th2 activation is observed in lung-associated lymph nodes, and no respiratory allergen immune characteristics are induced[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice with Allergic contact dermatitis (female, 7 weeks old)[1]
-
Dosage:1% (sensitization); 0.01% (challenge), 0.1% (challenge)
-
Administration:topical; on days 1-3, 8-10, 15-17 (sensitization); topical; single dose on day 31 (challenge)
-
Result:Did not cause statistically significant increases in total serum IgE levels in any furathiocarb-treated groups relative to controls.
Caused statistically significant increases in total lymphocyte counts, MHC Class II-positive B-cell counts, and IgE-positive B-cell counts in auricular lymph nodes at 0.1% challenge dose (after 1% sensitization) relative to control groups.
Caused IgE-positive B-cell counts to be significantly higher than in the low-dose challenge group at 0.1% challenge dose (after 1% sensitization).
Caused statistically significant increases in total lymphocyte counts and MHC Class II-positive B-cell counts in auricular lymph nodes at 0.01% challenge dose (after 1% sensitization) relative to non-sensitized controls.
Induced statistically significant increases in Th1 cytokines (IL-2, TNF-α, IFN-γ) and Th2 cytokines (IL-4, IL-5, IL-10, IL-13) in ex situ culture of auricular lymph node cells relative to controls, though Th2 cytokine responses were milder than those induced by 2,4-D.
-
Animal Model:BALB/c mice with Respiratory allergy (female, 7 weeks old)[1]
-
Dosage:1% (sensitization); 0.01% (challenge), 0.1% (challenge)
-
Administration:topical; on days 1-3, 8-10, 15-17 (sensitization); intratracheal; single dose on day 31 (challenge)
-
Result:Did not cause statistically significant increases in total IgE levels in serum or BALF in any furathiocarb-treated groups relative to controls.
Did not cause elevations in total or differential cell counts (eosinophils, neutrophils, macrophages) in BALF, aside from a mild, statistically significant increase in MIP-1β levels in the high-dose challenge group relative to controls.
Did not cause statistically significant increases in IgE-positive B-cell or MHC Class II-positive B-cell counts in lung-associated lymph nodes.
Did not induce statistically significant increases in Th2 cytokines (IL-4, IL-10, IL-13) in ex situ culture of lung-associated lymph node cells relative to controls.
Chemical Information
-
CAS. Nr. 65907-30-4
-
Appearance Oil
-
Molecular Weight 382.48
-
Formel C18H26N2O5S
-
Color Colorless to light yellow
-
SMILES
O=C(OC1=CC=CC2=C1OC(C)(C)C2)N(SN(C(=O)OCCCC)C)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (261.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.54 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.54 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (731 KB)
- English - EN (731 KB)
- Français - FR (731 KB)
- Deutsch - DE (731 KB)
- Norwegian - NO (731 KB)
- Español - ES (731 KB)
- Swedish - SV (731 KB)
- Italian - IT (731 KB)
- Korean - KR (731 KB)
- Portuguese - PT (731 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6145 mL | 13.0726 mL | 26.1452 mL | 65.3629 mL |
| 5 mM | 0.5229 mL | 2.6145 mL | 5.2290 mL | 13.0726 mL | |
| 10 mM | 0.2615 mL | 1.3073 mL | 2.6145 mL | 6.5363 mL | |
| 15 mM | 0.1743 mL | 0.8715 mL | 1.7430 mL | 4.3575 mL | |
| 20 mM | 0.1307 mL | 0.6536 mL | 1.3073 mL | 3.2681 mL | |
| 25 mM | 0.1046 mL | 0.5229 mL | 1.0458 mL | 2.6145 mL | |
| 30 mM | 0.0872 mL | 0.4358 mL | 0.8715 mL | 2.1788 mL | |
| 40 mM | 0.0654 mL | 0.3268 mL | 0.6536 mL | 1.6341 mL | |
| 50 mM | 0.0523 mL | 0.2615 mL | 0.5229 mL | 1.3073 mL | |
| 60 mM | 0.0436 mL | 0.2179 mL | 0.4358 mL | 1.0894 mL | |
| 80 mM | 0.0327 mL | 0.1634 mL | 0.3268 mL | 0.8170 mL | |
| 100 mM | 0.0261 mL | 0.1307 mL | 0.2615 mL | 0.6536 mL |